Please use this identifier to cite or link to this item: https://doi.org/10.1158/1078-0432.CCR-04-0493
Title: Loss of parafibromin immunoreactivity is a distinguishing feature of parathyroid carcinoma
Authors: Tan, M.-H.
Morrison, C.
Wang, P.
Yang, X.
Haven, C.J.
Zhang, C.
Zhao, P.
Tretiakova, M.S.
Korpi-Hyovalti, E.
Burgess, J.M.
Khee, C.S.
Cheah, W.-K. 
Cao, B.
Resau, J.
Morreau, H.
Bin, T.T.
Issue Date: 1-Oct-2004
Source: Tan, M.-H., Morrison, C., Wang, P., Yang, X., Haven, C.J., Zhang, C., Zhao, P., Tretiakova, M.S., Korpi-Hyovalti, E., Burgess, J.M., Khee, C.S., Cheah, W.-K., Cao, B., Resau, J., Morreau, H., Bin, T.T. (2004-10-01). Loss of parafibromin immunoreactivity is a distinguishing feature of parathyroid carcinoma. Clinical Cancer Research 10 (19) : 6629-6637. ScholarBank@NUS Repository. https://doi.org/10.1158/1078-0432.CCR-04-0493
Abstract: Purpose: A reliable method for diagnosing parathyroid carcinoma has remained elusive over the years, resulting in its under-recognition and suboptimal therapy. Obtaining an accurate diagnosis has become an even more pressing matter with recent evidence that germline HRPT2 gene mutations are found in patients with apparently sporadic parathyroid carcinoma. There is a high prevalence of HRPT2 gene mutations and biallelic inactivation in parathyroid carcinoma. We hypothesize that loss of parafibromin, the protein product of the HRPT2 gene, would distinguish carcinoma from benign tissue. Experimental Design: We generated a novel antiparafibromin monoclonal antibody and performed immunostaining on 52 definite carcinoma specimens, 6 equivocal carcinoma specimens, 88 benign specimens, and 9 hyperparathyroidism-jaw tumor (HPT-JT) syndrome-related adenomas from patients with primary hyperparathyroidism from nine worldwide centers and one national database. Results: We report that the loss of parafibromin nuclear immunoreactivity has 96% sensitivity [95% confidence interval (CI), 85-99%] and 99% specificity (95% CI, 92-100%) in diagnosing definite carcinoma. Inter-observer agreement for evaluation of parafibromin loss was excellent, with unweighted kappa of 0.89 (95% CI, 0.79-0.98). Two equivocal carcinomas misclassified as adenomas were high-lighted by parafibromin immunostaining. One of these tumors has since recurred, satisfying criteria for a definite carcinoma. Similarly, eight of nine HPT-JT syndrome-related adenomas showed absent nuclear immunoreactivity. Conclusions: Parafibromin is a promising molecular marker for diagnosing parathyroid carcinoma. The similar loss of parafibromin immunoreactivity in HPT-JT syndrome-related adenomas suggests that this is a pivotal step in parathyroid temorigenesis.
Source Title: Clinical Cancer Research
URI: http://scholarbank.nus.edu.sg/handle/10635/132664
ISSN: 10780432
DOI: 10.1158/1078-0432.CCR-04-0493
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
There are no files associated with this item.

SCOPUSTM   
Citations

154
checked on Apr 2, 2018

WEB OF SCIENCETM
Citations

128
checked on Apr 2, 2018

Page view(s)

5
checked on Mar 11, 2018

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.